Ichinose Y, Tsuchiya R, Koike T, Kuwahara O, Nakagawa K, Yamato Y, Kobayashi K, Watanabe Y, Kase M, Yokoi K
Department of Chest Surgery, National Kyushu Cancer Center, Fukuoka, Japan.
Surg Today. 2000;30(12):1062-6. doi: 10.1007/s005950070002.
Non-small cell lung cancer with carcinomatous pleuritis is considered to be a contraindication of surgical resection. The objective of this study was to clarify the prognosis of patients with non-small cell lung cancer in whom carcinomatous pleuritis was found at thoracotomy. A questionnaire survey on the survival of patients with carcinomatous pleuritis found at thoracotomy between January 1985 and December 1994 was conducted by the Japan Clinical Oncology Group. According to the data collected from 21 hospitals, 8813 patients with non-small cell lung cancer underwent thoracotomy, 284 (3.2%) of whom were found to have carcinomatous pleuritis. Information on survival was available for 227 of these patients, 34 (15%) of whom underwent thoracotomy alone without resection, whereas 193 (85%) underwent surgical resection. Of the 193 resected patients, 155 had no macroscopical residual tumor apart from the carcinomatous pleuritis. The 5-year survival rate was 14%. According to a univariate analysis, female sex, the presence of adenocarcinoma, a tumor size of less than 3.0 cm, no clinical lymph node metastasis, and no macroscopical residual tumor had a significantly favorable impact on survival. A multivariate analysis revealed that the extent of clinical lymph node metastasis (P = 0.006), histology (P = 0.028), and the absence or presence of a macroscopic residual tumor after the operation (P = 0.045) were predominant prognostic factors. The 5-year survival rate of 83 patients with three positive variables was 24%. The prognosis of patients with adenocarcinoma found to have carcinomatous pleuritis at thoracotomy was not necessarily unfavorable if there was no clinically detected lymph node metastasis and no residual tumor apart from the carcinomatous pleuritis.
伴有癌性胸膜炎的非小细胞肺癌被视为手术切除的禁忌证。本研究的目的是阐明在开胸手术中发现癌性胸膜炎的非小细胞肺癌患者的预后情况。日本临床肿瘤学组对1985年1月至1994年12月期间在开胸手术中发现癌性胸膜炎的患者生存情况进行了问卷调查。根据从21家医院收集的数据,8813例非小细胞肺癌患者接受了开胸手术,其中284例(3.2%)被发现患有癌性胸膜炎。这些患者中有227例可获得生存信息,其中34例(15%)仅接受了开胸手术而未进行切除,而193例(85%)接受了手术切除。在193例接受切除的患者中,155例除癌性胸膜炎外无肉眼可见的残留肿瘤。5年生存率为14%。单因素分析显示,女性、腺癌的存在、肿瘤大小小于3.0 cm、无临床淋巴结转移以及无肉眼可见的残留肿瘤对生存有显著的有利影响。多因素分析显示,临床淋巴结转移程度(P = 0.006)、组织学类型(P = 0.028)以及手术后有无肉眼可见的残留肿瘤(P = 0.045)是主要的预后因素。83例有三个阳性变量的患者的5年生存率为24%。如果在开胸手术中发现癌性胸膜炎的腺癌患者没有临床检测到的淋巴结转移且除癌性胸膜炎外无残留肿瘤,其预后不一定不佳。